Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Debt to Equity (2018 - 2024)

Neurocrine Biosciences filings provide 6 years of Debt to Equity readings, the most recent being $0.05 for Q1 2024.

  • On a quarterly basis, Debt to Equity changed N/A to $0.05 in Q1 2024 year-over-year; TTM through Mar 2024 was $0.05, a N/A change, with the full-year FY2023 number at $0.08, down 23.17% from a year prior.
  • Debt to Equity hit $0.05 in Q1 2024 for Neurocrine Biosciences, down from $0.08 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.53 in Q3 2020 to a low of $0.05 in Q1 2024.
  • Median Debt to Equity over the past 4 years was $0.1 (2022), compared with a mean of $0.19.
  • The widest YoY moves for Debt to Equity: up 22.53% in 2023, down 23.17% in 2023.
  • Neurocrine Biosciences' Debt to Equity stood at $0.53 in 2020, then plummeted by 81.23% to $0.1 in 2022, then fell by 23.17% to $0.08 in 2023, then tumbled by 32.47% to $0.05 in 2024.
  • The last three reported values for Debt to Equity were $0.05 (Q1 2024), $0.08 (Q4 2023), and $0.08 (Q3 2023) per Business Quant data.